These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 2011933)
1. Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion. Lim SH; Callaghan T; Goldstone AH Acta Haematol; 1991; 85(1):49-50. PubMed ID: 2011933 [TBL] [Abstract][Full Text] [Related]
2. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. Weijl NI; Van der Harst D; Brand A; Kooy Y; Van Luxemburg S; Schroder J; Lentjes E; Van Rood JJ; Cleton FJ; Osanto S J Clin Oncol; 1993 Jul; 11(7):1376-83. PubMed ID: 8315436 [TBL] [Abstract][Full Text] [Related]
3. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Macdonald D; Jiang YZ; Gordon AA; Mahendra P; Oskam R; Palmer PA; Franks CR; Barrett AJ Leuk Res; 1990; 14(11-12):967-73. PubMed ID: 2280612 [TBL] [Abstract][Full Text] [Related]
4. Thyroid functions in patients treated with interleukin-2 and lymphokine-activated killer cells. Kung AW; Lai CL; Wong KL; Tam CF Q J Med; 1992 Jan; 82(297):33-42. PubMed ID: 1332102 [TBL] [Abstract][Full Text] [Related]
5. Amplification of the graft-versus-leukemia effect in man by interleukin-2. Verdonck LF; van Heugten HG; Giltay J; Franks CR Transplantation; 1991 May; 51(5):1120-4. PubMed ID: 2031266 [No Abstract] [Full Text] [Related]
6. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha. Reid I; Sharpe I; McDevitt J; Maxwell W; Emmons R; Tanner WA; Monson JR Br J Cancer; 1991 Nov; 64(5):915-8. PubMed ID: 1931616 [TBL] [Abstract][Full Text] [Related]
8. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. Sievers EL; Lange BJ; Sondel PM; Krailo MD; Gan J; Liu-Mares W; Feig SA J Clin Oncol; 1998 Mar; 16(3):914-9. PubMed ID: 9508173 [TBL] [Abstract][Full Text] [Related]
9. Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Silvestri F; Virgolini L; Mazzolini A; Bertolissi F; Russo D; Fanin R; Baccarani M Haematologica; 1994; 79(4):367-70. PubMed ID: 7806093 [TBL] [Abstract][Full Text] [Related]
10. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cortes JE; Kantarjian HM; O'Brien S; Giles F; Keating MJ; Freireich EJ; Estey EH Cancer; 1999 Apr; 85(7):1506-13. PubMed ID: 10193940 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379 [TBL] [Abstract][Full Text] [Related]
12. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729 [TBL] [Abstract][Full Text] [Related]
13. Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease. Boughton BJ; Simpson AW Cytokines Cell Mol Ther; 1999 Mar; 5(1):1-6. PubMed ID: 10390074 [TBL] [Abstract][Full Text] [Related]
14. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. Kruit WH; Bolhuis RL; Goey SH; Jansen RL; Eggermont AM; Batchelor D; Schmitz PI; Stoter G J Clin Oncol; 1993 May; 11(5):921-4. PubMed ID: 8487055 [TBL] [Abstract][Full Text] [Related]
18. Patients treated with interferon-alpha, interferon-beta, and interleukin-2 have a different thyroid autoantibody pattern than patients suffering from endogenous autoimmune thyroid disease. Schuppert F; Rambusch E; Kirchner H; Atzpodien J; Kohn LD; von zur Mühlen A Thyroid; 1997 Dec; 7(6):837-42. PubMed ID: 9459625 [TBL] [Abstract][Full Text] [Related]
19. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620 [TBL] [Abstract][Full Text] [Related]
20. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Sievers EL; Lange BJ; Sondel PM; Krailo MD; Gan J; Tjoa T; Liu-Mares W; Feig SA Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S39-44. PubMed ID: 10685657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]